NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET.
In: Clinical Trials Week, 2023-04-03, S. 454-454
serialPeriodical
Zugriff:
Patients whose cancer worsens may receive re-treatment with 177Lu-DOTATATE IV on study. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate Patients of childbearing potential must have agreed to use a highly effective contraceptive method during protocol treatment and for 7 months after the last dose of protocol treatment. Patient will be considered eligible if an ultrasound is negative for pregnancy Patients must be accessible for treatment, response assessment, and follow up. [Extracted from the article]
Copyright of Clinical Trials Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET.
|
---|---|
Zeitschrift: | Clinical Trials Week, 2023-04-03, S. 454-454 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-6772 (print) |
Schlagwort: |
|
Sonstiges: |
|